“Nearly all diseases stem from a molecular mechanism going wrong,” writes Sergei Yakneen, chief technology officer of Alphabet’s Isomorphic Labs in a recent blog post. “Whether it’s an infectious agent disrupting our cellular machinery or a breakdown in processes like DNA repair, identifying the right protein and finding molecules to interact with it is…
SciBite Chat: Elsevier’s answer to ChatGPT for life science researchers, minus the hallucinations
The life sciences industry is abuzz with the potential of generative AI, but its application in the highly regulated pharmaceutical sector faces challenges. As Jane Lomax, Ph.D., head of ontologies at Elsevier’s SciBite subsidiary notes, “Everyone across the whole industry is experimenting with it. But no one knows for sure yet how best to use…
Insilico Medicine’s latest AI-engineered drug ISM5411 could provide a novel approach for treating IBD
Capping off a busy 2023, Insilico Medicine has announced a potentially first-in-class oral PHD inhibitor for the treatment of inflammatory bowel disease (IBD). ISM5411 is the fifth AI-backed drug candidate from Insilico Medicine to reach clinical stages. ISM5411 targets prolyl hydroxylase domain (PHD) enzymes via modulation of the hypoxia-inducible factor (HIF) pathway, which is involved…
Using AlphaFold, Insilico Medicine produces AI drug discovery in record time
An international group of researchers employed DeepMind’s deep learning-driven AlphaFold protein structure database to design and synthesize a potential hepatocellular carcinoma (HCC) drug in only 30 days. The AI drug discovery project consisted of Insilico Medicine, the University of Toronto’s Acceleration Consortium and researchers including Nobel laureate Michael Levitt. The team applied AlphaFold to Insilico’s…
Fueling breakthroughs in pharma AI: 3 critical factors
Big data and AI offer massive opportunities to the pharmaceutical industry — in theory. In reality, many companies are struggling to realize the potential of these tools. Some organizations have been hesitant or resistant to leveraging the technologies. Others may have attempted to embrace them early on but are now beginning their second or third…